Short Interest in Seelos Therapeutics, Inc. (NASDAQ:SEEL) Rises By 116.8%

Seelos Therapeutics, Inc. (NASDAQ:SEEL) was the recipient of a large growth in short interest during the month of July. As of July 15th, there was short interest totalling 295,000 shares, a growth of 116.8% from the June 30th total of 136,100 shares. Based on an average daily volume of 488,800 shares, the days-to-cover ratio is currently 0.6 days. Currently, 10.9% of the company’s stock are short sold.

Seelos Therapeutics Stock Down 6.6 %

Shares of NASDAQ:SEEL traded down $0.03 during trading on Friday, hitting $0.44. 298,842 shares of the company were exchanged, compared to its average volume of 1,329,906. Seelos Therapeutics has a fifty-two week low of $0.43 and a fifty-two week high of $398.40. The firm has a fifty day moving average price of $0.85 and a two-hundred day moving average price of $4.14.

Seelos Therapeutics (NASDAQ:SEEL) last posted its quarterly earnings results on Tuesday, May 14th. The company reported ($1.60) earnings per share for the quarter. The business had revenue of $0.58 million during the quarter.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Seelos Therapeutics stock. Gendell Jeffrey L lifted its holdings in shares of Seelos Therapeutics, Inc. (NASDAQ:SEEL) by 284.3% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 428,966 shares of the company’s stock after acquiring an additional 317,351 shares during the quarter. Gendell Jeffrey L owned approximately 2.58% of Seelos Therapeutics worth $254,000 as of its most recent SEC filing. Institutional investors own 23.37% of the company’s stock.

About Seelos Therapeutics

Seelos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD).